Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Scinopharm Taiwan's share price for the quarter that ended in Dec. 2025 was NT$16.75. Scinopharm Taiwan's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 791 Mil. Therefore, Scinopharm Taiwan's market cap for the quarter that ended in Dec. 2025 was NT$13,245 Mil.
Scinopharm Taiwan's quarterly market cap
increased
from Jun. 2025 (NT$13,443 Mil) to Sep. 2025 (NT$14,985 Mil) but then
declined
from Sep. 2025 (NT$14,985 Mil) to Dec. 2025 (NT$13,245 Mil).
Scinopharm Taiwan's annual market cap
declined
from Dec. 2023 (NT$20,876 Mil) to Dec. 2024 (NT$17,436 Mil) and
declined
from Dec. 2024 (NT$17,436 Mil) to Dec. 2025 (NT$13,245 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Scinopharm Taiwan's Enterprise Value for Today is NT$13,981 Mil.
Scinopharm Taiwan (TPE:1789) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Scinopharm Taiwan Market Cap Related Terms
Scinopharm Taiwan Market Cap Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Market Cap distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Scinopharm Taiwan's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Market Cap of NT$16,329 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Scinopharm Taiwan and its competitors. According to the industry distribution chart, Scinopharm Taiwan ranks #387 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 37.9%.
Is Scinopharm Taiwan's Market Cap too high?
Scinopharm Taiwan's current Market Cap is NT$16,329 Mil. Based on the distribution chart, Scinopharm Taiwan ranks #387 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #387 out of 1022 companies for Market Cap. This puts Scinopharm Taiwan in the upper half of its industry. The industry median Market Cap is 210.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Market Cap is NT$16,329 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.10, compared to a current price of NT$20.65 — trading 23.8% below its estimated fair value. The current Market Cap is NT$16,329 Mil. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Market Cap is NT$16,329 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.65 is trading 23.8% below its estimated GF Value™ of NT$27.10.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Market Cap: NT$16,329 Mil
GF Value™: NT$27.10 vs. price of NT$20.65 (23.8% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
